

Application No.: 10/523,498

2

Docket No.: 59563(71699)

Listing of the Claims

This listing of the claims replaces all previous versions of the claims.

1-7. (Canceled)

8. (Currently Amended) ~~A The peptide compound of claim 28, consisting of the amino acid sequence set forth as which selectively binds to the extracellular portion of human PSMA and is at least 60% identical to a peptide compound selected from the group consisting of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, and 107.~~

9-27. (Canceled)

28. (New) A peptide compound which selectively binds to the extracellular portion of human PSMA and comprises at least 5 residues in common with the consensus sequence QKHHNYL (SEQ ID NO:109).

29. (New) The peptide of claim 28, wherein the peptide has at least 6 residues in common with the consensus sequence QKHHNYL (SEQ ID NO:109).

30. (New) The peptide of claim 28, wherein the peptide has the consensus sequence QKHHNYL (SEQ ID NO:109).

31. (New) The peptide of claim 30, wherein the peptide is 9 amino acid residues in length.

32. (New) The peptide of claim 28 or 31, wherein the peptide comprises a cysteine residue at the N and C terminus.

579120

Application No.: 10/523,498

3

Docket No.: 59563(71699)

33. (New) The peptide of claim 32, wherein the peptide is cyclic.

34. (New) The peptide of claim 28, wherein the peptide comprises one or more amino acid analogues.

579120